All In Biotech

Drug Trial Radar · NCT07715305

A Clinical Trial to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers

An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers Under Fasting Conditions

Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

44

Planned (sponsor's estimate)

Start

Jul 2026

Primary completion

Aug 2026

Study completion Aug 2026

Sponsor

Lead sponsor
Addpharma Inc.Industry
Sponsor type
Industry
First posted
Jul 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study compare and evaluate the bioequivalence between the administration of AD-116A and the administration of AD-1161 in healthy adult male volunteers

Conditions

  • Benign Prostatic Hyperplasia

Interventions

  • AD-116ADrug

    Oral Capsule

  • AD-1161Drug

    Oral Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the plasma concentration-time curve during dosing interval (AUCt)Time frame: pre-dose (0hour) to 72hours
  2. Maximum concentration of drug in plasma (Cmax)Time frame: pre-dose (0hour) to 72hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • H PLUS YANGJI HOSPITAL, Seoul

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.